{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH+-+Nonalcoholic+Steatohepatitis%3B+NAFLD+-+Nonalcoholic+Fatty+Liver+Disease&page=6",
    "query": {
      "condition": "NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 307,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH+-+Nonalcoholic+Steatohepatitis%3B+NAFLD+-+Nonalcoholic+Fatty+Liver+Disease&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH+-+Nonalcoholic+Steatohepatitis%3B+NAFLD+-+Nonalcoholic+Fatty+Liver+Disease&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T08:00:01.065Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06932289",
      "title": "Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "NAFLD (Nonalcoholic Fatty Liver Disease)"
      ],
      "interventions": [
        {
          "name": "Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "The integrated sweat sensor and vascular sensor (wearable)",
          "type": "DEVICE"
        },
        {
          "name": "continuous glucose monitor (CGM)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DEVICE"
      ],
      "sponsor": "VA Greater Los Angeles Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2025-05-01",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06932289"
    },
    {
      "nct_id": "NCT05232071",
      "title": "Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lanifibranor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inventiva Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2022-06-29",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 26,
      "location_summary": "Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05232071"
    },
    {
      "nct_id": "NCT04048135",
      "title": "A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NASH"
      ],
      "interventions": [
        {
          "name": "Pegozafermin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "89bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 101,
      "start_date": "2019-07-29",
      "completion_date": "2022-01-19",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 25,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04048135"
    },
    {
      "nct_id": "NCT06318169",
      "title": "A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis"
      ],
      "interventions": [
        {
          "name": "Pegozafermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "89bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1350,
      "start_date": "2024-03-13",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 154,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06318169"
    },
    {
      "nct_id": "NCT05010070",
      "title": "The University of Michigan Wellness for Liver Health Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "diet and lifestyle program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2021-08-31",
      "completion_date": "2022-10-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010070"
    },
    {
      "nct_id": "NCT04321031",
      "title": "Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease",
        "Nonalcoholic Steatohepatitis With Liver Fibrosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-06865571",
          "type": "DRUG"
        },
        {
          "name": "PF-05221304",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 256,
      "start_date": "2020-06-15",
      "completion_date": "2024-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 184,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04321031"
    },
    {
      "nct_id": "NCT02854605",
      "title": "Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "GS-9674",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match GS-9674",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 140,
      "start_date": "2016-10-26",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02854605"
    },
    {
      "nct_id": "NCT02781584",
      "title": "Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)",
        "Nonalcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "FIR",
          "type": "DRUG"
        },
        {
          "name": "CILO",
          "type": "DRUG"
        },
        {
          "name": "FENO",
          "type": "DRUG"
        },
        {
          "name": "VAS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2016-06-13",
      "completion_date": "2020-12-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 12,
      "location_summary": "Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781584"
    },
    {
      "nct_id": "NCT02891408",
      "title": "Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Firsocostat",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2016-09-23",
      "completion_date": "2019-05-13",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 5,
      "location_summary": "Tustin, California • Miami, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02891408"
    },
    {
      "nct_id": "NCT03042767",
      "title": "Anti-LPS Antibody Treatment for Pediatric NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "IMM-124E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Miriam Vos, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "6 Years to 19 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-02-01",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-23T08:00:01.065Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03042767"
    }
  ]
}